Results 191 to 200 of about 1,501,016 (387)
Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis
Arthritis &Rheumatology, EarlyView.Osteoporosis is a chronic disease, and antiresorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used antiresorptive treatments, bisphosphonates and denosumab, have short‐ and long‐term risks that, coupled with their benefits and other unique characteristics, influence ...
Giovanni Adami, Kenneth G. Saag
wiley +1 more source
Arthritis &Rheumatology, Accepted Article.Objective This study characterized the impact of voclosporin on kidney histology in patients with lupus nephritis (LN) who had protocolized repeat kidney biopsies in the AURORA clinical trials. Methods Patients were randomized to voclosporin or placebo treatment for up to three years; all patients received mycophenolate mofetil and low‐dose ...
Brad H. Rovin +9 more
wiley +1 more source
A comparative trial of clonidine, propranolol and placebo in the treatment of moderate hypertension. [PDF]
, 1977 P. Wilkinson, E. B. Raftery
openalex +1 more source
Gout and NLRP3 Inflammasome Biology
Arthritis &Rheumatology, EarlyView.This review describes the three broad stages of acute inflammation in the context of gout: initiation, leucocyte mobilization, and self‐resolution. A typical case of a gout flare is presented. The role of the NLRP3 inflammasome in acute monosodium urate crystal–induced inflammation is reviewed in detail.
Raewyn Poulsen, Nicola Dalbeth
wiley +1 more source
PETHIDINE COMPARED WITH PETHIDINE PLUS LEVALLORPHAN AND WITH A PLACEBO
, 1965 P J Tomlin
openalex +1 more source
A PLACEBO‐CONTROLLED COMPARISON OF THE SEDATIVE PROPERTIES OF THREE BENZODIAZEPINES, LORAZEPAM, FLUNITRAZEPAM AND FOSAZEPAM [PDF]
, 1977 J. W. Dundee +4 more
openalex +1 more source
Arthritis &Rheumatology, Accepted Article.Objective The SEMAPHORE trial evaluated the efficacy and safety of tocilizumab (TCZ) in glucocorticoid (GC)‐dependent polymyalgia rheumatica (PMR). TCZ reduced GC use and disease activity at 24 weeks. This study aimed to assess relapse rates after stopping TCZ in patients achieving remission at week 24.
Baptiste Chevet +24 more
wiley +1 more source